Symeres expands spray drying capabilities at Cranbury CMC site for poorly soluble drug candidates
The investment integrates ASD development, formulation sciences, and analytical characterisation under one roof — supporting BCS Class II and IV compounds from preclinical screening through to Phase II clinical materials